NO329227B1 - Anvendelse av borreliacidal(e) epitoper av Borrelia burgdorferi ytre overflateprotein C som vaksine - Google Patents

Anvendelse av borreliacidal(e) epitoper av Borrelia burgdorferi ytre overflateprotein C som vaksine Download PDF

Info

Publication number: NO329227B1
Authority: NO; Norway
Prior art keywords: ospc; antibody; seq; borreliacidal; fragment
Prior art date: 1998-07-31

Application number

NO20010412A

Other languages

English (en)

Norwegian (no)

Other versions

NO20010412L (no

NO20010412D0 (no

Inventor

Ronald F Schell

Steven M Callister

Steven D Lovrich

Dean A Jobe

Original Assignee

Gundersen Lutheran Medical Fou

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-31

Filing date

2001-01-24

Publication date

2010-09-20

2001-01-24 Application filed by Gundersen Lutheran Medical Fou filed Critical Gundersen Lutheran Medical Fou

2001-01-24 Publication of NO20010412D0 publication Critical patent/NO20010412D0/no

2001-03-29 Publication of NO20010412L publication Critical patent/NO20010412L/no

2010-09-20 Publication of NO329227B1 publication Critical patent/NO329227B1/no

Links

230000001449 borreliacidal effect Effects 0.000 title abstract description 82
229960005486 vaccine Drugs 0.000 title description 19
101900341261 Borrelia burgdorferi Outer surface protein C Proteins 0.000 title 1
108700023315 OspC Proteins 0.000 claims abstract description 109
239000012634 fragment Substances 0.000 claims abstract description 101
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 44
238000000034 method Methods 0.000 claims abstract description 16
241000589969 Borreliella burgdorferi Species 0.000 claims abstract description 9
238000002965 ELISA Methods 0.000 claims description 43
208000015181 infectious disease Diseases 0.000 claims description 42
229920001184 polypeptide Polymers 0.000 claims description 42
102000004196 processed proteins & peptides Human genes 0.000 claims description 42
125000003275 alpha amino acid group Chemical group 0.000 claims description 28
108020004414 DNA Proteins 0.000 claims description 24
241000124008 Mammalia Species 0.000 claims description 17
206010061591 Borrelia infection Diseases 0.000 claims description 10
102000053602 DNA Human genes 0.000 claims description 9
239000002671 adjuvant Substances 0.000 claims description 7
210000001124 body fluid Anatomy 0.000 claims description 6
239000010839 body fluid Substances 0.000 claims description 6
230000002163 immunogen Effects 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 5
239000000203 mixture Substances 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
230000021615 conjugation Effects 0.000 claims description 4
238000003745 diagnosis Methods 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
239000013604 expression vector Substances 0.000 claims description 4
239000002773 nucleotide Substances 0.000 claims description 3
125000003729 nucleotide group Chemical group 0.000 claims description 3
101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 claims description 2
208000016604 Lyme disease Diseases 0.000 abstract description 70
108090000623 proteins and genes Proteins 0.000 abstract description 17
241001465754 Metazoa Species 0.000 abstract description 14
102000004169 proteins and genes Human genes 0.000 abstract description 14
230000000694 effects Effects 0.000 abstract description 11
238000011282 treatment Methods 0.000 abstract description 8
238000013399 early diagnosis Methods 0.000 abstract description 2
230000002265 prevention Effects 0.000 abstract description 2
238000012216 screening Methods 0.000 abstract description 2
230000004927 fusion Effects 0.000 abstract 1
210000002966 serum Anatomy 0.000 description 41
238000002255 vaccination Methods 0.000 description 32
108700006640 OspA Proteins 0.000 description 31
210000004369 blood Anatomy 0.000 description 27
239000008280 blood Substances 0.000 description 27
238000012360 testing method Methods 0.000 description 21
239000002953 phosphate buffered saline Substances 0.000 description 19
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 18
241000589970 Spirochaetales Species 0.000 description 17
241000282412 Homo Species 0.000 description 16
229920001213 Polysorbate 20 Polymers 0.000 description 16
101150055083 ospC gene Proteins 0.000 description 16
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 16
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 16
239000003599 detergent Substances 0.000 description 13
238000010790 dilution Methods 0.000 description 12
239000012895 dilution Substances 0.000 description 12
102000037865 fusion proteins Human genes 0.000 description 12
108020001507 fusion proteins Proteins 0.000 description 12
241000282472 Canis lupus familiaris Species 0.000 description 11
230000005875 antibody response Effects 0.000 description 11
238000001514 detection method Methods 0.000 description 11
241000238876 Acari Species 0.000 description 10
238000011534 incubation Methods 0.000 description 10
239000013612 plasmid Substances 0.000 description 10
241000588724 Escherichia coli Species 0.000 description 9
241000699670 Mus sp. Species 0.000 description 9
238000002835 absorbance Methods 0.000 description 9
238000003556 assay Methods 0.000 description 9
239000000463 material Substances 0.000 description 9
230000035945 sensitivity Effects 0.000 description 9
239000000725 suspension Substances 0.000 description 9
238000001179 sorption measurement Methods 0.000 description 8
239000007434 bsk-medium Substances 0.000 description 7
239000000872 buffer Substances 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
230000004044 response Effects 0.000 description 7
230000003321 amplification Effects 0.000 description 6
239000000427 antigen Substances 0.000 description 6
102000036639 antigens Human genes 0.000 description 6
108091007433 antigens Proteins 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
229940042470 lyme disease vaccine Drugs 0.000 description 6
238000003199 nucleic acid amplification method Methods 0.000 description 6
238000000746 purification Methods 0.000 description 6
108091028043 Nucleic acid sequence Proteins 0.000 description 5
238000002405 diagnostic procedure Methods 0.000 description 5
239000000523 sample Substances 0.000 description 5
238000001262 western blot Methods 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
241000701022 Cytomegalovirus Species 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
229960000723 ampicillin Drugs 0.000 description 4
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
230000028993 immune response Effects 0.000 description 4
230000006698 induction Effects 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
210000001503 joint Anatomy 0.000 description 4
239000011347 resin Substances 0.000 description 4
229920005989 resin Polymers 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
241001473877 Biserrula isolate Species 0.000 description 3
241000483002 Euproctis similis Species 0.000 description 3
241000609499 Palicourea Species 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000027455 binding Effects 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000010367 cloning Methods 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000008030 elimination Effects 0.000 description 3
238000003379 elimination reaction Methods 0.000 description 3
230000008029 eradication Effects 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
102000013415 peroxidase activity proteins Human genes 0.000 description 3
108040007629 peroxidase activity proteins Proteins 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
239000013598 vector Substances 0.000 description 3
240000003291 Armoracia rusticana Species 0.000 description 2
235000011330 Armoracia rusticana Nutrition 0.000 description 2
108090001008 Avidin Proteins 0.000 description 2
241000589968 Borrelia Species 0.000 description 2
241001148604 Borreliella afzelii Species 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
102000012410 DNA Ligases Human genes 0.000 description 2
108010061982 DNA Ligases Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
206010062488 Erythema migrans Diseases 0.000 description 2
101000578940 Homo sapiens PDZ domain-containing protein MAGIX Proteins 0.000 description 2
-1 Isopropyl- Chemical group 0.000 description 2
241000238703 Ixodes scapularis Species 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
102100028326 PDZ domain-containing protein MAGIX Human genes 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
102400000368 Surface protein Human genes 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
KBTZIRDXUNOZMF-UHFFFAOYSA-N benzene-1,2-diamine;phosphoric acid Chemical compound OP(O)(O)=O.NC1=CC=CC=C1N KBTZIRDXUNOZMF-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000029087 digestion Effects 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
230000037406 food intake Effects 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
230000003902 lesion Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
210000001539 phagocyte Anatomy 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
235000017550 sodium carbonate Nutrition 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
235000011149 sulphuric acid Nutrition 0.000 description 2
208000006379 syphilis Diseases 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000005382 thermal cycling Methods 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
229940125575 vaccine candidate Drugs 0.000 description 2
UPLPHRJJTCUQAY-WIRWPRASSA-N 2,3-thioepoxy madol Chemical compound C([C@@H]1CC2)[C@@H]3S[C@@H]3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 UPLPHRJJTCUQAY-WIRWPRASSA-N 0.000 description 1
101710157236 41 kDa protein Proteins 0.000 description 1
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
239000005996 Blood meal Substances 0.000 description 1
241001148605 Borreliella garinii Species 0.000 description 1
206010062746 Carditis Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
241000256135 Chironomus thummi Species 0.000 description 1
108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
108010069112 Complement System Proteins Proteins 0.000 description 1
102000000989 Complement System Proteins Human genes 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
206010011831 Cytomegalovirus infection Diseases 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000699694 Gerbillinae Species 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
241000238681 Ixodes Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
208000009525 Myocarditis Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
210000003495 flagella Anatomy 0.000 description 1
230000006870 function Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000036541 health Effects 0.000 description 1
230000008076 immune mechanism Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000010185 immunofluorescence analysis Methods 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
208000021646 inflammation of heart layer Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
208000030175 lameness Diseases 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000007479 molecular analysis Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
208000020470 nervous system symptom Diseases 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000014207 opsonization Effects 0.000 description 1
230000003571 opsonizing effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
235000020030 perry Nutrition 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
239000000843 powder Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000010998 test method Methods 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229940040944 tetracyclines Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
239000012137 tryptone Substances 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
229940124856 vaccine component Drugs 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Pathology (AREA)
Tropical Medicine & Parasitology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Communicable Diseases (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

NO20010412A 1998-07-31 2001-01-24 Anvendelse av borreliacidal(e) epitoper av Borrelia burgdorferi ytre overflateprotein C som vaksine NO329227B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9495598P	1998-07-31	1998-07-31
PCT/US1999/017270 WO2000006745A1 (en)	1998-07-31	1999-07-30	Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine

Publications (3)

Publication Number	Publication Date
NO20010412D0 NO20010412D0 (no)	2001-01-24
NO20010412L NO20010412L (no)	2001-03-29
NO329227B1 true NO329227B1 (no)	2010-09-20

Family

ID=22248146

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20010412A NO329227B1 (no)	1998-07-31	2001-01-24	Anvendelse av borreliacidal(e) epitoper av Borrelia burgdorferi ytre overflateprotein C som vaksine

Country Status (13)

Country	Link
US (2)	US6210676B1 (de)
EP (1)	EP1100922B1 (de)
JP (1)	JP3631960B2 (de)
AT (1)	ATE386805T1 (de)
AU (1)	AU5328299A (de)
CA (1)	CA2332570C (de)
CY (1)	CY1107944T1 (de)
DE (1)	DE69938183T2 (de)
DK (1)	DK1100922T3 (de)
ES (1)	ES2302385T3 (de)
NO (1)	NO329227B1 (de)
PT (1)	PT1100922E (de)
WO (1)	WO2000006745A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7008625B2 (en)	1993-11-01	2006-03-07	Research Foundation Of The State University Of New York	Recombinant constructs of Borrelia burgdorferi
US7060281B1 (en)	1999-06-18	2006-06-13	Research Foundation Of The State University Of New York	Groups of barrelia burgdorferi and borrelia afzelii that cause lyme disease in humans
AU2001281145A1 (en) *	2000-08-18	2002-03-04	Brookhaven Sciences Associates, Llc	Recombinant constructs of borrelia burgdorferi
EP1865062A3 (de) *	2000-08-18	2008-01-09	Research Foundation Of State University Of New York	Verändertes OspA der Borrelia burgdorferi
ATE381575T1 (de) *	2000-08-18	2008-01-15	Univ New York State Res Found	Veränderte borrelia burgdorferi ospa
EP1939294A1 (de) *	2000-08-18	2008-07-02	Research Foundation Of State University Of New York	Rekombinante Konstrukte von Borrelia Burgdorferi
US20020142355A1 (en) *	2000-11-14	2002-10-03	Baylor College Of Medicine	Methods for the in vivo biotin labeling of polypeptides
RU2260047C2 (ru) *	2003-10-23	2005-09-10	Государственное учреждение Научно-исследовательский институт биохимии Сибирского отделения Российской академии медицинских наук	Рекомбинантная плазмидная днк, обеспечивающая синтез иммунодоминантного белка borrelia garinii, используемого для диагностики лайм-боррелиоза (варианты)
UA99719C2 (ru) *	2006-11-03	2012-09-25	Шеринг-Плау Лтд.	Вакцина для собак против болезни лайма
WO2008116468A2 (en)	2007-03-26	2008-10-02	Dako Denmark A/S	Mhc peptide complexes and uses thereof in infectious diseases
EP3620465B1 (de)	2007-07-03	2025-02-19	Dako Denmark A/S	Verbesserte verfahren zur herstellung, markierung und verwendung von mhc-multimeren
US10611818B2 (en)	2007-09-27	2020-04-07	Agilent Technologies, Inc.	MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da)	2008-02-28	2019-09-09	Dako Denmark As	MHC-multimerer til Borrelia-diagnostik og sygdom
US20110262475A1 (en) *	2008-05-02	2011-10-27	Earnhart Christopher G	Lyme disease vaccine
WO2010009735A2 (en)	2008-07-23	2010-01-28	Dako Denmark A/S	Combinatorial analysis and repair
GB0817244D0 (en)	2008-09-20	2008-10-29	Univ Cardiff	Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en)	2008-10-02	2024-05-28	Agilent Technologies, Inc.	Molecular vaccines for infectious disease
WO2010037402A1 (en)	2008-10-02	2010-04-08	Dako Denmark A/S	Molecular vaccines for infectious disease
CN103229055A (zh)	2010-09-27	2013-07-31	康奈尔大学	莱姆病的诊断方法
US8808705B2 (en) *	2010-10-20	2014-08-19	Virginia Commonwealth University	Polyvalent chimeric OspC vaccinogen and diagnostic antigen
UY34745A (es)	2012-04-18	2013-11-29	Zoetis Llc	Vacunas y procedimientos para tratar la enfermedad de lyme en perros
US9562079B2 (en)	2012-04-18	2017-02-07	Zoetis Services Llc	Vaccines and methods to treat lyme disease in dogs
WO2016049148A1 (en)	2014-09-24	2016-03-31	Wellstat Diagnostics, Llc	Compositions and methods for te diagnosis of lyme disease
EP3720489A1 (de)	2017-12-04	2020-10-14	Intervet International B.V.	Lyme-impfstoff für hunde
WO2020127222A2 (en)	2018-12-17	2020-06-25	Immudex Aps	Panel comprising borrelia mhc multimers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5777095A (en)	1988-10-24	1998-07-07	Symbicom Aktiebolag	Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US5385826A (en)	1989-04-21	1995-01-31	Gundersen Medical Foundation, Ltd.	Diagnostic assay for lyme disease
DE4015911A1 (de)	1989-09-19	1991-03-28	Max Planck Gesellschaft	Impfstoff gegen die lyme-krankheit
EP0519016A1 (de)	1990-03-07	1992-12-23	F.Hoffmann-La Roche & Co. Aktiengesellschaft	Verfahren zur diagnose der lyme-krankheit
CA2084413A1 (en)	1990-06-15	1991-12-16	Richard A. Flavell	Compositions and methods for the prevention and diagnosis of lyme disease
FI955150A7 (fi) *	1993-04-29	1995-12-28	Baxter Ag	OspC-antigeenirokotteiden immunogeenisia formulaatioita lyymisairauden ehkäisyyn ja hoitoon ja rekombinanttimenetelmiä antigeenien valmistam iseksi
US5656451A (en)	1993-07-30	1997-08-12	Yale University	OspE, OspF, and S1 polypeptides in borrelia burgdorferi
WO1995011998A1 (en) *	1993-10-26	1995-05-04	United Biomedical, Inc.	Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics
US5558993A (en)	1994-06-17	1996-09-24	The Regents Of The University Of California	Cloned Borrelia burgdorferi virulence protein
US5853987A (en)	1995-04-24	1998-12-29	The Texas A & M University System	Decorin binding protein compositions and methods of use
DE69731982T2 (de)	1996-03-26	2005-12-22	Cylex, Inc.	Verfahren zur messung der lymphozytenfunktion
DE69718903T2 (de) *	1996-05-02	2003-12-04	Dakocytomation Denmark A/S, Glostrup	Verwendung von aus osp-c abgeleiteten peptidefragmenten für diagnostische methoden
US5846946A (en)	1996-06-14	1998-12-08	Pasteur Merieux Serums Et Vaccins	Compositions and methods for administering Borrelia DNA

1999
- 1999-07-30 EP EP99938897A patent/EP1100922B1/de not_active Expired - Lifetime
- 1999-07-30 JP JP2000562527A patent/JP3631960B2/ja not_active Expired - Fee Related
- 1999-07-30 PT PT99938897T patent/PT1100922E/pt unknown
- 1999-07-30 AU AU53282/99A patent/AU5328299A/en not_active Abandoned
- 1999-07-30 AT AT99938897T patent/ATE386805T1/de active
- 1999-07-30 ES ES99938897T patent/ES2302385T3/es not_active Expired - Lifetime
- 1999-07-30 CA CA002332570A patent/CA2332570C/en not_active Expired - Lifetime
- 1999-07-30 DE DE69938183T patent/DE69938183T2/de not_active Expired - Lifetime
- 1999-07-30 DK DK99938897T patent/DK1100922T3/da active
- 1999-07-30 WO PCT/US1999/017270 patent/WO2000006745A1/en not_active Ceased
- 1999-07-30 US US09/364,083 patent/US6210676B1/en not_active Expired - Lifetime
2000
- 2000-08-30 US US09/651,419 patent/US6464985B1/en not_active Expired - Lifetime
2001
- 2001-01-24 NO NO20010412A patent/NO329227B1/no not_active IP Right Cessation
2008
- 2008-05-13 CY CY20081100502T patent/CY1107944T1/el unknown

Also Published As

Publication number	Publication date
CY1107944T1 (el)	2013-09-04
DE69938183D1 (de)	2008-04-03
NO20010412L (no)	2001-03-29
CA2332570A1 (en)	2000-02-10
JP2002523019A (ja)	2002-07-30
CA2332570C (en)	2009-12-08
ATE386805T1 (de)	2008-03-15
DE69938183T2 (de)	2009-02-19
JP3631960B2 (ja)	2005-03-23
US6464985B1 (en)	2002-10-15
PT1100922E (pt)	2008-05-30
EP1100922B1 (de)	2008-02-20
EP1100922A1 (de)	2001-05-23
WO2000006745A1 (en)	2000-02-10
AU5328299A (en)	2000-02-21
ES2302385T3 (es)	2008-07-01
NO20010412D0 (no)	2001-01-24
US6210676B1 (en)	2001-04-03
DK1100922T3 (da)	2008-06-16

Legal Events

Date	Code	Title	Description
2016-02-29	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO329227B1 (no)	2010-09-20	Anvendelse av borreliacidal(e) epitoper av Borrelia burgdorferi ytre overflateprotein C som vaksine
Rousselle et al.	1998	Borreliacidal antibody production against outer surface protein C of Borrelia burgdorferi
Demaerschalck et al.	1995	Simultaneous presence of different Borrelia burgdorferi genospecies in biological fluids of Lyme disease patients
JP5390189B2 (ja)	2014-01-15	多価キメラｏｓｐｃワクシノーゲンおよび診断用抗原
Lovrich et al.	1995	Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection
EP0345299A1 (de)	1989-12-13	Mycobacterium tuberculosis-gene, kodierend für proteinantigene
Fikrig et al.	1995	Vaccination against Lyme disease caused by diverse Borrelia burgdorferi.
Wallich et al.	1993	Molecular and immunological characterization of a novel polymorphic lipoprotein of Borrelia burgdorferi
AU683260B2 (en)	1997-11-06	Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
EP0524958A1 (de)	1993-02-03	Antigen-wirkende proteine von -i(borrelia burgdorferi).
JP2013542942A (ja)	2013-11-28	多価キメラｏｓｐｃワクシノーゲンおよび診断用抗原
Sjöstedt et al.	1989	Molecular cloning and expression of a T-cell stimulating membrane protein of Francisella tularensis
AU699416B2 (en)	1998-12-03	Nucleic acids of (rochalimaea henselae) and (rochalimaea quintana) and methods and compositions for diagnosing (rochalimaea henselae) and (rochalimaea quintana) infection
WO1992012235A1 (en)	1992-07-23	FLAGELLA-LESS $i(BORRELIA)
US6685945B2 (en)	2004-02-03	Cloned Leptospira outer membrane protein
WO2013033092A2 (en)	2013-03-07	Streptococcus suis pilus antigens
US6296855B1 (en)	2001-10-02	17-KDA Brucella abortus antigen, recombinant polypeptides, nucleic acids coding for the same and use thereof in diagnostic and prophylactic methods and kits
AU712882B2 (en)	1999-11-18	Leptospira membrane proteins
EP1056865A2 (de)	2000-12-06	Aussen-membran protein von leptospira, lipl32
Coyle et al.	1995	Management of Lyme disease
EP0693936B1 (de)	2002-09-18	Cloniertes protein der äusseren membran von leptospira
Fikrig et al.	1996	Borrelia burgdorferi
US6248583B1 (en)	2001-06-19	Chromosomally-encoded membrane protein of borrelia burgdorferi
Wikel et al.	0	OspE-Related, OspF-Related, and Elp